JMP Securities Cuts Lantheus (NASDAQ:LNTH) Price Target to $125.00

Lantheus (NASDAQ:LNTH) had its target price cut by JMP Securities from $130.00 to $125.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a market outperform rating on the medical equipment provider’s stock.

Other equities analysts have also recently issued research reports about the company. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a buy rating in a research report on Thursday, July 25th. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a buy rating for the company in a report on Thursday. SVB Leerink upped their price target on Lantheus from $106.00 to $127.00 and gave the company an outperform rating in a report on Thursday, July 11th. StockNews.com cut Lantheus from a buy rating to a hold rating in a report on Friday, May 3rd. Finally, Mizuho upped their price target on Lantheus from $90.00 to $100.00 and gave the company a buy rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Lantheus has an average rating of Moderate Buy and an average price target of $119.00.

Lantheus Stock Performance

LNTH opened at $97.59 on Thursday. The company has a market cap of $6.78 billion, a PE ratio of 14.90 and a beta of 0.51. The stock has a 50-day moving average of $92.18 and a 200-day moving average of $73.37. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.55 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business’s revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.40 EPS. As a group, equities research analysts forecast that Lantheus will post 6.46 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total value of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Heinz Christoph Maeusli sold 18,373 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the sale, the chief accounting officer now owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,799 shares of company stock worth $3,769,262. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Silverberg Bernstein Capital Management LLC boosted its position in Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after buying an additional 100 shares during the last quarter. Moody National Bank Trust Division boosted its position in Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after buying an additional 162 shares during the last quarter. Shaker Investments LLC OH boosted its position in Lantheus by 0.7% in the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after buying an additional 182 shares during the last quarter. NBC Securities Inc. boosted its position in Lantheus by 28.4% in the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 191 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.